Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IIIBiomarker/Laboratory analysis, Tissue collection/Repository, Treatment18 and overN0577
NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146

Trial Description

Summary

This randomized phase III trial compares giving radiation therapy alone or temozolomide together with radiation therapy and to see which works best in treating patients with newly diagnosed anaplastic glioma or low grade glioma. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy alone or temozolomide together with radiation therapy is better in treating anaplastic glioma or low grade glioma.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine whether patients who receive radiotherapy with concomitant temozolomide followed by adjuvant temozolomide (radiation therapy [RT] + temozolomide [TMZ] → TMZ) (ARM B) have a marginally better progression free survival (PFS) as compared with patients who receive radiotherapy followed by adjuvant procarbazine hydrochloride, lomustine, vincristine sulfate (PCV) chemotherapy (RT → PCV) (ARM A).

SECONDARY OBJECTIVES:

I. To determine whether patients who receive temozolomide RT + TMZ → TMZ have a significantly longer time to progression (clinical or radiographic progression) as compared with patients who receive radiotherapy followed by adjuvant chemotherapy (RT → PCV).

II. To determine whether there is a difference in survival based on t(1;19)(q10,p10) translocation status and O-6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) promoter hypermethylation status.

III. To perform descriptive comparisons of additional secondary outcome endpoints, including overall survival, objective tumor response, prognostic factor analysis and quality of life.

IV. To determine the toxicity of the treatment in each arm and perform descriptive comparisons.

V. To determine the neurocognitive and quality of life (QOL) effects in patients treated on this protocol and correlate these results with outcome endpoints.

VI. To store blood products (i.e., plasma, DNA, and buffy coat), tumor tissue and magnetic resonance imaging (MRI)/computed tomography (CT) images for future scientific investigations.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients undergo 3-dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) on days 1-5. Patients also receive procarbazine hydrochloride orally (PO) on days 8-21, lomustine PO on day 1 and vincristine sulfate intravenously (IV) on days 8 and 29 of courses 3-8 for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM B: Patients undergo IMRT as in Arm A and receive temozolomide PO once daily (QD) on days 1-5 for 6 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for 6-12 courses in the absence of disease progression and unacceptable toxicity.

After completion of study therapy, patients are followed up every 12 weeks for 1 year, every 4 months for 2 years, and then every 6 months thereafter.

Eligibility Criteria

Inclusion Criteria:

Willing to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion of the study)

Tumor tissue must show co-deletion for the relevant portions of chromosomes 1p and 19q by fluorescence in situ hybridization (FISH) analysis, as defined by the testing laboratory

Patients with co-deleted low grade gliomas must also be considered "high risk" by clinical criteria utilized in Radiation Therapy Oncology Group (RTOG) 9802 and must be either:

Age >= 40 and any surgical therapy

Age < 40 and subtotal resection or biopsy

Patient willing to provide tissue samples for correlative research purposes

Provide informed written consent

Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2

Willing and able to complete neurocognitive testing without assistance and the QOL by themselves or with assistance

Negative serum or urine pregnancy test done =< 7 days prior to registration, for women of childbearing potential only

Creatinine =< 1.5 x ULN

Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x ULN

Hemoglobin (Hgb) > 9.0 g/dL

Platelet (PLTs) count >= 100,000/mm^3

Absolute neutrophil count (ANC) >= 1,500/mm^3

Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered from the effects of surgery

Histological confirmation of anaplastic glioma (oligodendroglioma, mixed, or astrocytoma [World Health Organization (WHO) grade 2 or 3]), or low grade glioma (WHO grade 2), as determined by pre-registration central pathology review; Note: mixed gliomas are eligible, regardless of the degree of astrocytic or oligodendrocytic predominance, as long as the tumor is also co-deleted for 1p and 19q

Newly diagnosed and =< 3 months from surgical diagnosis

REGISTRATION INCLUSION CRITERIA:

Patients must be willing to submit tissue samples for mandatory central pathology review submission and deletion status determination; it should be initiated as soon after surgery as possible

PRE-REGISTRATION INCLUSION CRITERIA:

Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

Exclusion Criteria:

Receiving any other investigational agent that would be considered as a treatment for the primary neoplasm

Concomitant serious immunocompromised status (other than that related to concomitant steroids) that would compromise the safety of the patient on the study

Recent history of hepatitis infection or treating physician determined that the patient would be at significant risk of reactivation of hepatitis

History of myocardial infarction =< 6 months or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

Other active malignancy within 5 years of registration; exceptions: non-melanotic skin cancer or carcinoma in situ of the cervix; Note: if there is a history of prior malignancy, the patient must not be receiving other specific treatment (other than hormonal therapy) for their cancer

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for the study

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Received any prior surgery, radiation therapy or chemotherapy for any central nervous system (CNS) neoplasm; Note: patients who have had a prior low grade glioma with/without surgery and who now have anaplastic glioma with no prior radiation or chemotherapy are eligible for the study

Any of the following:

Pregnant women

Nursing women

Men or women of childbearing potential who are unwilling to employ adequate contraception during this study and for up to 6 months following the completion of temozolomide treatments

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

Alliance for Clinical Trials in Oncology

  • National Cancer Institute
  • European Organization for Research and Treatment of Cancer
Kurt A. Jaeckle, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

John B. Fiveash
Ph: 205-934-0309

John B. Fiveash
Principal Investigator

Alaska
Anchorage

Alaska Women's Cancer Care

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Anchorage Oncology Centre

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Alaska Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Arizona
Phoenix

Saint Joseph's Hospital and Medical Center

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

David G. Brachman
Principal Investigator

California
Fresno

California Cancer Center - North Fresno

Uzair Bashir Chaudhary
Ph: 559-447-4050

Uzair Bashir Chaudhary
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Santosh Kesari
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Santosh Kesari
Principal Investigator

Los Angeles

Cedars-Sinai Medical Center

Jethro Lisien Hu
Ph: 310-423-8965

Jethro Lisien Hu
Principal Investigator

Colorado
Aurora

The Medical Center of Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Florida
Jacksonville

Mayo Clinic in Florida

Kurt A. Jaeckle
Ph: 507-538-7623

Kurt A. Jaeckle
Principal Investigator

Georgia
Atlanta

Piedmont Hospital

Adam Wayne Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Adam Wayne Nowlan
Principal Investigator

Illinois
Chicago

Northwestern University

Priya Uday Kumthekar
Ph: 312-695-1301
Email: cancer@northwestern.edu

Priya Uday Kumthekar
Principal Investigator

Maywood

Loyola University Medical Center

Edward Melian
Ph: 708-226-4357

Edward Melian
Principal Investigator

Park Ridge

Advocate Lutheran General Hospital.

Heather E. Leeper
Ph: 847-384-3621

Heather E. Leeper
Principal Investigator

Indiana
South Bend

Memorial Hospital of South Bend

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Clive

Medical Oncology and Hematology Associates-West Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Cancer Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Des Moines

Iowa Lutheran Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Iowa Oncology Research Association CCOP

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Des Moines

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Medical Oncology and Hematology Associates-Laurel

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

West Des Moines

Mercy Medical Center-West Lakes

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Methodist West Hospital

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Kentucky
Louisville

Norton Hospital Pavilion and Medical Campus

Aaron C. Spalding
Ph: 502-629-2500

Aaron C. Spalding
Principal Investigator

Maryland
Baltimore

Johns Hopkins University/Sidney Kimmel Cancer Center

Matthias Holdhoff
Ph: 410-955-8804
Email: jhcccro@jhmi.edu

Matthias Holdhoff
Principal Investigator

Rockville

Cancer Trials Support Unit

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Massachusetts
Boston

Massachusetts General Hospital Cancer Center

Helen A. Shih
Ph: 877-726-5130

Helen A. Shih
Principal Investigator

Michigan
Detroit

Henry Ford Hospital

Robert Anthony Chapman
Ph: 313-916-1784

Robert Anthony Chapman
Principal Investigator

Grand Rapids

Mercy Health Saint Mary's

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Spectrum Health at Butterworth Campus

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Peter Y. Chen
Ph: 248-551-7695

Peter Y. Chen
Principal Investigator

Traverse City

Munson Medical Center

Gilbert D.A. Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Gilbert D.A. Padula
Principal Investigator

Troy

William Beaumont Hospital - Troy

Peter Y. Chen
Ph: 248-551-7695

Peter Y. Chen
Principal Investigator

Minnesota
Burnsville

Fairview Ridges Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Coon Rapids

Mercy Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Edina

Fairview-Southdale Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Fridley

Unity Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint John's Hospital - Healtheast

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Hennepin County Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Saint Paul

Regions Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

United Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Waconia

Ridgeview Medical Center

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Willmar

Rice Memorial Hospital

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Patrick James Flynn
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Patrick James Flynn
Principal Investigator

Missouri
Saint Louis

Washington University School of Medicine

Jian Li Campian
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Jian Li Campian
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Vincent Healthcare

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Kearney

CHI Health Good Samaritan

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Omaha

Alegent Health Bergan Mercy Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Alegent Health Immanuel Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Alegent Health Lakeside Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Missouri Valley Cancer Consortium

Gamini S. Soori
Ph: 402-991-8070ext202
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Papillion

Midlands Community Hospital

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

New Hampshire
Lebanon

Dartmouth Hitchcock Medical Center

Camilo Enrique Fadul
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Camilo Enrique Fadul
Principal Investigator

New Jersey
New Brunswick

Rutgers Cancer Institute of New Jersey

Sabin Bhagwan Motwani
Ph: 732-235-8675

Sabin Bhagwan Motwani
Principal Investigator

UMDNJ - Robert Wood Johnson University Hospital

Sabin Bhagwan Motwani
Ph: 732-235-8675

Sabin Bhagwan Motwani
Principal Investigator

New Mexico
Albuquerque

University of New Mexico

Fa-Chyi Lee
Ph: 505-272-6972

Fa-Chyi Lee
Principal Investigator

New York
Rochester

Highland Hospital

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

University of Rochester

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

North Dakota
Grand Forks

Altru Cancer Center

Grant Richard Seeger
Ph: 701-780-6520

Grant Richard Seeger
Principal Investigator

Ohio
Cleveland

Case Western Reserve University

Joseph Gibbons
Ph: 800-641-2422

Joseph Gibbons
Principal Investigator

Cleveland Clinic Foundation

Samuel Tay Chao
Ph: 866-223-8100

Samuel Tay Chao
Principal Investigator

Columbus

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Ohio State University Comprehensive Cancer Center

Kurt A. Jaeckle
Email: jaeckle.kurt@mayo.edu

Kurt A. Jaeckle
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Wooster

Cleveland Clinic Wooster Specialty Center

Samuel Tay Chao
Ph: 866-223-8100

Samuel Tay Chao
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Gresham

Legacy Mount Hood Medical Center

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

Portland

Legacy Good Samaritan Hospital and Medical Center

Andrew Y. Kee
Ph: 507-538-7623

Andrew Y. Kee
Principal Investigator

Providence Portland Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Saint Vincent Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Pennsylvania
Abington

Abington Memorial Hospital

Willard G. Andrews
Ph: 215-481-2402

Willard G. Andrews
Principal Investigator

Bethlehem

Saint Luke's University Hospital-Bethlehem Campus

Hugh D. Moulding
Ph: 610-954-3582
Email: infolink@slhn.org

Hugh D. Moulding
Principal Investigator

Philadelphia

Thomas Jefferson University Hospital

Jon Glass
Ph: 215-955-6084

Jon Glass
Principal Investigator

Pittsburgh

University of Pittsburgh Cancer Institute (UPCI)

David Anthony Clump
Ph: 412-621-2334

David Anthony Clump
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Scott Michael Lindhorst
Ph: 843-792-9321

Scott Michael Lindhorst
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Andrews

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Butternut

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Joshua Cole Lukenbill
Ph: 605-716-3982
Email: research@rcrh.org

Joshua Cole Lukenbill
Principal Investigator

Tennessee
Nashville

Vanderbilt University/Ingram Cancer Center

Paul L. Moots
Ph: 800-811-8480

Paul L. Moots
Principal Investigator

Texas
Dallas

UT Southwestern/Simmons Cancer Center-Dallas

Edward Pan
Ph: 214-648-7097

Edward Pan
Principal Investigator

Galveston

University of Texas Medical Branch

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

League City

UTMB Cancer Center at Victory Lakes

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Martin Colman
Principal Investigator

Utah
Cedar City

Sandra L Maxwell Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Murray

Intermountain Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Provo

Utah Valley Regional Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Salt Lake City

LDS Hospital

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Utah Cancer Specialists-Salt Lake City

R. Jeffrey Lee
Ph: 801-507-3950

R. Jeffrey Lee
Principal Investigator

Virginia
Richmond

Virginia Commonwealth University/Massey Cancer Center

Mark G. Malkin
Ph: 804-628-1939

Mark G. Malkin
Principal Investigator

Washington
Seattle

Virginia Mason CCOP

Craig R. Nichols
Ph: 503-215-6412
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Craig R. Nichols
Principal Investigator

Virginia Mason Medical Center

Craig R. Nichols
Ph: 503-215-6412
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Craig R. Nichols
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Wisconsin
La Crosse

Gundersen Lutheran Medical Center

Collin D. Driscoll
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Collin D. Driscoll
Principal Investigator

Milwaukee

Froedtert and the Medical College of Wisconsin

Joseph A. Bovi
Ph: 414-805-4380

Joseph A. Bovi
Principal Investigator

Waukesha

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-5539
Email: Chanda.miller@phci.org

Timothy Robert Wassenaar
Principal Investigator

Austria

Vienna

Medical University Vienna

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Belgium

Antwerpen

Alegemeen Ziekenhuis Middelheim

Kurt A. Jaeckle
Ph: 904-953-7102
Email: jaeckle.kurt@mayo.edu

Kurt A. Jaeckle
Principal Investigator

France

Lyon

Centre Leon Berard

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Nice

Centre Antoine Lacassagne

Kurt A. Jaeckle
Ph: 904-953-7102
Email: jaeckle.kurt@mayo.edu

Kurt A. Jaeckle
Principal Investigator

Villejuif

Institut Gustave Roussy

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Netherlands

Amsterdam

Academ Zienkenhuis Bij De University

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Groningen

University Medical Center Groningen

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Maastricht

Maastro Clinic-Maastricht Radiation Oncology

Kurt A. Jaeckle
Ph: 904-953-7102
Email: jaeckle.kurt@mayo.edu

Kurt A. Jaeckle
Principal Investigator

Rotterdam

Erasmus University Medical Center

Kurt A. Jaeckle

Kurt A. Jaeckle
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00887146

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.